Welcome to our dedicated page for Aptevo Therapeutics news (Ticker: APVO), a resource for investors and traders seeking the latest updates and insights on Aptevo Therapeutics stock.
Aptevo Therapeutics Inc. develops clinical-stage immune-oncology therapeutics for cancer using its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies. News about APVO centers on mipletamig, its CD123 x CD3 program for acute myeloid leukemia, including clinical data, safety observations, orphan drug designation for AML, and combination studies with venetoclax and azacitidine.
Company updates also cover pipeline expansion into bispecific, multispecific and trispecific candidates, solid-tumor work such as ALG.APV-527, conference presentations, financing arrangements, operating results, shareholder voting matters, and governance changes tied to Aptevo’s public-company structure.
Aptevo Therapeutics (APVO) reported a 93% clinical benefit rate for its mipletamig triplet regimen in evaluable frontline TP53‑mutated acute myeloid leukemia (AML) patients. Of 14 patients treated with mipletamig plus venetoclax and azacitidine, 13 derived clinical benefit and 11 (79%) achieved complete remission (CR) or CR with incomplete hematologic recovery (CRi).
The 79% CR/CRi rate compares with a published 41% composite remission rate for venetoclax plus azacitidine alone in treatment‑naïve TP53‑mutated AML with poor‑risk cytogenetics. The ongoing RAINIER Phase 1b/2 trial is in dose optimization and is expected to complete this phase by year‑end, with regulatory interaction planned in 1H27. Mipletamig, Aptevo’s lead wholly owned bispecific candidate, has orphan drug designation for AML and is designed to target CD123‑expressing leukemic cells while aiming to limit cytokine release syndrome.
Aptevo Therapeutics (NASDAQ: APVO) reported its 2Q26 business update, emphasizing clinical progress of lead candidate mipletamig in frontline acute myeloid leukemia (AML), non-dilutive funding for trispecific candidate APVO451, and expansion into radiopharmaceuticals through a 50/50 collaboration with Niowave.
In the Phase 1b/2 RAINIER trial, mipletamig plus venetoclax and azacitidine showed an 87% clinical benefit rate and 81% remission rate across 31 evaluable unfit frontline AML patients, with 55% of CR/CRi patients reaching MRD-negative status and six patients proceeding to allogeneic transplant. Aptevo received a $1.5 million non-dilutive grant to support APVO451 IND-enabling work and targets development candidate selection by year-end 2026. The Niowave collaboration covers up to three radiopharmaceutical programs and includes an equity investment giving Niowave an initial 7.9% ownership, potentially rising to 19.99%. Aptevo reported $9.8 million in cash and cash equivalents as of June 30, 2026, and raised $0.6 million via its SEPA facility during the quarter.
Aptevo Therapeutics (NASDAQ:APVO) closed a previously announced warrant inducement transaction and a concurrent private placement (PIPE), generating aggregate gross proceeds of approximately $4.5 million before fees. Holders exercised Existing Warrants for cash to purchase 254,922 shares of common stock at $4.03 per share, and received new Inducement Warrants to purchase up to 1,274,610 additional shares at the same exercise price. The Inducement Warrants become exercisable only after required stockholder approval and expire five years after such approval.
Separately, under a securities purchase agreement, Aptevo sold in a PIPE up to 861,708 unregistered shares at $4.03 per share, or alternatively Pre-Funded Warrants, together with Common Warrants to purchase up to 4,308,540 shares at $4.03. PIPE Warrants also require stockholder approval and carry five-year terms post-approval. According to the company, net proceeds will be used for working capital. The securities were issued in private placements under exemptions to registration, and Aptevo plans to file a registration statement covering resale of the relevant shares.
Aptevo Therapeutics (NASDAQ: APVO) entered into warrant inducement agreements under which certain holders will exercise in full 254,922 existing common stock warrants for cash at a reduced exercise price of $4.03 per share. In exchange, Aptevo will issue new unregistered Inducement Warrants to purchase up to 1,274,610 shares at an exercise price of $4.03, exercisable after required stockholder approval and expiring five years after initial exercise.
Separately, Aptevo agreed to a PIPE financing selling up to 861,708 unregistered shares at $4.03 per share, or pre-funded warrants in lieu of shares, plus Common Warrants to purchase up to 4,308,540 shares at $4.03. Pre-funded warrants are exercisable immediately; Common Warrants become exercisable after stockholder approval and expire five years after initial exercise. Aggregate gross proceeds from these transactions are expected to be about $4.5 million before fees, with closing expected on or about August 13, 2026. Aptevo plans to use net proceeds for working capital.
Aptevo Therapeutics (NASDAQ:APVO) has filed a patent application for a proprietary Nectin-4 x PD-L1 dual-targeting backbone intended to underpin a new solid tumor strategy. The reusable backbone is designed to support multiple modalities, including radiopharmaceuticals, T‑cell engagers and other immune-based therapies, from a single platform-derived construct.
According to Aptevo, the backbone leverages Nectin-4 expression on several solid tumors and PD-L1 on tumor and immune-suppressive cells to enhance tumor localization and anti-tumor immunity. The filing is positioned to strengthen Aptevo’s intellectual property, expand partnering opportunities and demonstrate the versatility of its ADAPTIR and ADAPTIR-FLEX platforms.
Aptevo (NASDAQ:APVO) received a $1.5 million non-dilutive research grant from the Andy Hill CARE Fund to support IND-enabling work for APVO451, a nectin-4-targeted trispecific immunotherapy for solid tumors.
The grant funds preclinical and development activities toward development candidate selection by year-end 2026 and IND-enabling studies in Q1 2027.
Aptevo Therapeutics (Nasdaq: APVO) appointed Mary J. Janatpour, Ph.D. as Senior Vice President & Chief Scientific Officer to lead research and preclinical development.
She brings 25+ years of oncology R&D experience, supporting Aptevo's multispecific immuno-oncology pipeline, mipletamig clinical focus, and its new radiopharmaceutical collaboration with Niowave.
Aptevo (Nasdaq: APVO) and Niowave entered a 50/50 strategic collaboration to develop up to three radiopharmaceutical oncology programs. Niowave made an at-the-market equity investment, taking a 7.9% stake, with potential ownership up to 19.99% via premium-priced warrants and future stock purchases.
Aptevo contributes multispecific antibody assets, initially targeting Nectin-4, while Niowave supplies radioisotopes including Actinium-225. The first stage of the collaboration is designed and ready to initiate, aiming to create targeted radiopharmaceutical therapies for cancers with high unmet need.
Aptevo Therapeutics (NASDAQ:APVO) reported a Q1 2026 business update highlighting mipletamig data in frontline AML, leadership changes, and new financing.
Mipletamig showed an 87% clinical benefit rate, 81% CR/CRi, 65% CR, 52% MRD-negative among CR/CRi, and no CRS in frontline patients across 31 evaluable patients.
The RAINIER trial remains on track for completion and Phase 2 dose selection by year end. Jeff Lamothe became CEO, Marvin White Executive Chair. Aptevo held $14.5 million in cash on March 31, 2026, and secured a new $60 million SEPA extending capital access into 2029.
Aptevo (Nasdaq:APVO) reported topline RAINIER frontline AML data through Cohort 5 showing 87% clinical benefit and 81% remission (CR/CRi) in 31 evaluable patients treated with mipletamig plus venetoclax and azacitidine. Cohorts 6–7 and two six-patient groups will complete the dataset for RP2D selection, with trial completion and Phase 2 dose selection on track for 2026.
Key numeric outcomes: 65% CR rate, 55% MRD-negativity among CR/CRi, 36% of remissions in TP53-mutant patients, six patients proceeded to allogeneic transplant, and no cytokine release syndrome reported.